What is a Biomarker in the Context of Tumors?

News
Video

Related Videos
Somedeb Ball, MBBS
Lauren E. Nye, MD
Jonathan E. Rosenberg, MD
Emil Lou, MD, PhD, FACP
Jean L. Koff, MD, MS
Rohan Garje, MD
Debu Tripathy, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Benjamin Garmezy, MD
Related Content
Erika Hamilton, MD

Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer

May 16th 2024
Article
Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

May 13th 2024
Podcast
Bruna Pellini, MD, of Moffitt Cancer Center and Research Institute

Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC

May 16th 2024
Article
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, professor, division head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; codirector, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute

Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors

May 9th 2024
Podcast
Rebecca A. Dent, MD, MSc, of National Cancer Center Singapore and Duke-NUS Medical School

Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC

May 15th 2024
Article
Breast Cancer - stock.adobe.com

Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer

May 15th 2024
Article